The final, formatted version of the article will be published soon.
STUDY PROTOCOL article
Front. Endocrinol.
Sec. Cardiovascular Endocrinology
Volume 16 - 2025 |
doi: 10.3389/fendo.2025.1522756
This article is part of the Research Topic Metabolic Pathways to Multiple Long-term Conditions (Multimorbidity): Focusing on Cardio-metabolic Multimorbidity (CMM) View all articles
Advancing Early Detection of Organ Damage and Cardiovascular Risk Prevention: The Suzhou Cardiometabolic Health (SCH) Study Protocol -Exploring the Role of Oral Microbiome and Metabolic Profiling in Risk Stratification
Provisionally accepted- 1 Cardiovascular Diseases Center, Xiyuan Hospital, Beijing, China
- 2 Suzhou hospital, Xiyuan hospital of China academy of Chinese medical sciences, Suzhou, Liaoning Province, China
Background: Cardiovascular Disease (CVD) is the leading cause of global mortality, with its incidence rate rising year by year due to the prevalence of metabolic diseases.Existing primary and secondary prevention strategies for cardiovascular disease have limitations in identifying some high-risk groups, and 1.5-level prevention aims to achieve more precise intervention by early identification of subclinical target organ damage. This study introduces oral (tongue coating) microbiota as metabolic markers for the first time, in combination with multiple metabolic factors, to explore their potential in assessing subclinical target organ damage and optimizing cardiovascular risk stratification, in order to provide a new path for the early identification and intervention of CVD.Methods: This study is a prospective cohort study aimed at assessing the association between tongue coating microbiota characteristics and multiple metabolic factors with subclinical target organ damage, and identifying high-risk groups suitable for cardiovascular 1.5-level prevention. The study will be conducted in Suzhou City, Jiangsu Province, China, planning to include 5000-6000 eligible subjects, with inclusion criteria of age ≥18 years, excluding individuals with a history of CVD and other serious diseases. Baseline assessment includes demographic information, lifestyle (including dietary patterns), medical history, physical examination, and collection of tongue coating microbiota samples. Subjects will be followed up every 2 years, with the primary outcome being the first occurrence of coronary heart disease and stroke, and the secondary outcome being subclinical target organ damage.Discussion: This study focuses on cardiovascular 1.5-level prevention strategy, combining metabolic factors with tongue coating microbiota characteristics, aiming to optimize the risk assessment system for subclinical target organ damage. This approach can not only fill the gap in traditional risk assessment but also provide new ideas for the early identification and intervention of CVD. In the future, the feasibility and effectiveness of this strategy will be verified through multicenter studies, and it is expected to be promoted to a wider medical system, significantly improving the health management level of high-risk groups for CVD.
Keywords: cardiovascular disease, metabolic risk factors, Subclinical target organ damage, Oral microbiota, risk stratification
Received: 05 Nov 2024; Accepted: 24 Jan 2025.
Copyright: © 2025 Zhu, Li, Wang, Liu, Liu, Yu, XU, Cui, Liu, Chen and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yue Liu, Cardiovascular Diseases Center, Xiyuan Hospital, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.